Joaquim Bellmunt, MD, PhD, on Bladder Cancer: The Future of Immunotherapies
2018 ASCO-SITC Clinical Immuno-Oncology SymposiumJoaquim Bellmunt, MD, PhD, of Dana-Farber Cancer Institute, discusses refining treatment choices with new combinations and sequencing strategies.
Related Videos
Kristen Fousek, PhD Candidate, on B-Cell ALL: CAR T-Cell Treatment
Kristen Fousek, PhD Candidate at Baylor College of Medicine, discusses her preclinical work on targeting CD19-negative relapsed B-cell acute lymphoblastic leukemia, using CAR T cel...
Sumanta K. Pal, MD, on Renal Cancer Immunotherapy: Latest Developments
Sumanta K. Pal, MD, of the City of Hope, discusses immunotherapy as a front-line treatment for kidney cancer and the strategy of VEGF blockade with immunotherapy, which is emerging...
Linda Mileshkin, MBBS, on Solid Tumors: Early Treatment Study Results
Linda Mileshkin, MBBS, of the Peter MacCallum Cancer Centre, discusses phase Ib trial findings on the anti–PD-1 monoclonal antibody BGB-A317 in combination with the PARP inhibitor ...
Stephen M. Ansell, MD, PhD, on Hematologic Malignancies: Immunotherapy Update
Stephen M. Ansell, MD, PhD, of the Mayo Clinic, discusses integrating immune checkpoint inhibitors, improving efficacy, and reducing toxicity when treating blood cancers.
Mary L. Disis, MD, on Basics of Immunology: An Overview
Mary L. Disis, MD, of the University of Washington, discusses innate and adaptive immune system cells, T cells as key to mediating antitumor immunity, and the mechanisms by which c...
